Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination

Xiaomei Zhang, Mei Zheng, Te Liang, Haijian Zhou, Hongye Wang, Jiahui Zhang, Jing Ren, Huoying Peng, Siping Li, Haodong Bian, Chundi Wei, Shangqi Yin, Chaonan He, Ying Han, Minghui Li, Xuexin Hou, Jie Zhang, Liangzhi Xie, Jing Lv, Biao Kan, Yajie Wang, Xiaobo Yu
doi: https://doi.org/10.1101/2021.05.15.21257254
Xiaomei Zhang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mei Zheng
2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Te Liang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haijian Zhou
4State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongye Wang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiahui Zhang
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Ren
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huoying Peng
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siping Li
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haodong Bian
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chundi Wei
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shangqi Yin
2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chaonan He
2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Han
2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minghui Li
4State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuexin Hou
4State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Zhang
6Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological, Inc., Beijing, 100176, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liangzhi Xie
6Beijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological, Inc., Beijing, 100176, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Lv
7Gobond Testing Technology (Beijing) Co., Ltd., Beijing, 102629, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Biao Kan
4State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xiaobo.yu{at}hotmail.com wangyajie{at}ccmu.edu.cn kanbiao{at}icdc.cn
Yajie Wang
2Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China
3Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China
5Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xiaobo.yu{at}hotmail.com wangyajie{at}ccmu.edu.cn kanbiao{at}icdc.cn
Xiaobo Yu
1State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: xiaobo.yu{at}hotmail.com wangyajie{at}ccmu.edu.cn kanbiao{at}icdc.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Mutations of the coronavirus responsible for coronavirus disease 2019 (COVID-19) could impede drug development and reduce the efficacy of COVID-19 vaccines. Here, we developed a multiplexed Spike-ACE2 Inhibitor Screening (mSAIS) assay that can measure the neutralizing effect of antibodies across numerous variants of the coronavirus’s Spike (S) protein simultaneously. By screening purified antibodies and serum from convalescent COVID-19 patients and vaccinees against 72 S variants with the mSAIS assay, we identified new S mutations that are sensitive and resistant to neutralization. Serum from both infected and vaccinated groups with a high titer of neutralizing antibodies (NAbs) displayed a broader capacity to neutralize S variants than serum with low titer NAbs. These data were validated using serum from a large vaccinated cohort (n=104) with a tiled S peptide microarray. In addition, similar results were obtained using a SARS-CoV-2 pseudovirus neutralization assay specific for wild-type S and four prevalent S variants (D614G, B.1.1.7, B.1.351, P.1), thus demonstrating that high antibody diversity is associated with high NAb titers. Our results demonstrate the utility of the mSAIS platform in screening NAbs. Moreover, we show that heterogeneous antibody populations provide a more protective effect against S variants, which may help direct COVID-19 vaccine and drug development.

Highlights

  • Developed a high throughput assay to screen the neutralizing effect of antibodies across multiple SARS-CoV-2 Spike variants simultaneously.

  • Characterized the heterogeneity of neutralizing antibodies produced in response to COVID-19 infection and vaccination.

  • Demonstrated the capacity of Spike variants neutralization is associated with the diversity of anti-Spike antibodies.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the National Natural Science Foundation of China (31870823), National Key R&D Program of China (2020YFE0202200), State Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201904, SKLP-O201703, SKLP-O202007), the National Program on Key Basic Research Project (2018YFA0507503, 2017YFC0906703, 2018ZX09733003) and the Beijing Municipal Education Commission, Beijing Municipal Natural Science Foundation (M21003) and Beijing Municipal Science&Technology Commission (Z201100001020001; Z201100005420022). We thank Dr. Brianne Petritis for her critical review and editing of this manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Our research was approved by the Ethics Committee of Beijing Ditan Hospital (No. 2021-010-01), and exemption of informed consent was obtained prior to sera collection.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The ability of the serological NAbs to inhibit the S-ACE2 interactions across the different S variants was visualized as a heatmap using the MultiExperiment Viewer software version 4.9 (Chu et al., 2008). Statistical analyses were performed using the GraphPad Prism software 8.3 and Microsoft Excel with the unpaired t test and Mann-Whitney test. A p-value (p) < 0.05 was considered to be significant. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001. The 3D structure of the SARS-CoV-2 RBD and ACE2 complex (PDB ID code: 6M0J) was visualized using the VMD 1.9.3, and mutations were annotated.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 18, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination
Xiaomei Zhang, Mei Zheng, Te Liang, Haijian Zhou, Hongye Wang, Jiahui Zhang, Jing Ren, Huoying Peng, Siping Li, Haodong Bian, Chundi Wei, Shangqi Yin, Chaonan He, Ying Han, Minghui Li, Xuexin Hou, Jie Zhang, Liangzhi Xie, Jing Lv, Biao Kan, Yajie Wang, Xiaobo Yu
medRxiv 2021.05.15.21257254; doi: https://doi.org/10.1101/2021.05.15.21257254
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination
Xiaomei Zhang, Mei Zheng, Te Liang, Haijian Zhou, Hongye Wang, Jiahui Zhang, Jing Ren, Huoying Peng, Siping Li, Haodong Bian, Chundi Wei, Shangqi Yin, Chaonan He, Ying Han, Minghui Li, Xuexin Hou, Jie Zhang, Liangzhi Xie, Jing Lv, Biao Kan, Yajie Wang, Xiaobo Yu
medRxiv 2021.05.15.21257254; doi: https://doi.org/10.1101/2021.05.15.21257254

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)